LT3873894T - Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra - Google Patents

Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra

Info

Publication number
LT3873894T
LT3873894T LTEPPCT/EP2019/079621T LTEP2019079621T LT3873894T LT 3873894 T LT3873894 T LT 3873894T LT EP2019079621 T LTEP2019079621 T LT EP2019079621T LT 3873894 T LT3873894 T LT 3873894T
Authority
LT
Lithuania
Prior art keywords
same
bcl
inhibitor
preparing
pharmaceutical compositions
Prior art date
Application number
LTEPPCT/EP2019/079621T
Other languages
English (en)
Inventor
Michael Lynch
Frédéric VILLARD
Patrick Mouchet
Pascal TAULELLE
Ludovic MASSON
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Publication of LT3873894T publication Critical patent/LT3873894T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/EP2019/079621T 2018-10-31 2019-10-30 Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra LT3873894T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306430 2018-10-31
PCT/EP2019/079621 WO2020089281A1 (en) 2018-10-31 2019-10-30 Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
LT3873894T true LT3873894T (lt) 2023-06-26

Family

ID=64270773

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2019/079621T LT3873894T (lt) 2018-10-31 2019-10-30 Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra

Country Status (37)

Country Link
US (1) US20210355108A1 (lt)
EP (1) EP3873894B1 (lt)
JP (1) JP2022506137A (lt)
KR (1) KR20210092750A (lt)
CN (1) CN112969693A (lt)
AR (1) AR116921A1 (lt)
AU (1) AU2019370926A1 (lt)
BR (1) BR112021007194A2 (lt)
CA (1) CA3117559C (lt)
CL (1) CL2021000947A1 (lt)
CO (1) CO2021005077A2 (lt)
CR (1) CR20210211A (lt)
CY (1) CY1126057T1 (lt)
DK (1) DK3873894T3 (lt)
DO (1) DOP2021000074A (lt)
EA (1) EA202191143A1 (lt)
ES (1) ES2943511T3 (lt)
FI (1) FI3873894T3 (lt)
GE (1) GEP20237494B (lt)
HR (1) HRP20230563T1 (lt)
HU (1) HUE062000T2 (lt)
IL (1) IL282565A (lt)
JO (1) JOP20210072A1 (lt)
LT (1) LT3873894T (lt)
MA (1) MA54063B1 (lt)
MX (1) MX2021004934A (lt)
NI (1) NI202100025A (lt)
PE (1) PE20211503A1 (lt)
PH (1) PH12021550790A1 (lt)
PL (1) PL3873894T3 (lt)
PT (1) PT3873894T (lt)
RS (1) RS64236B1 (lt)
SG (1) SG11202103594XA (lt)
SI (1) SI3873894T1 (lt)
TW (1) TWI791916B (lt)
WO (1) WO2020089281A1 (lt)
ZA (1) ZA202102783B (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023001307A2 (pt) 2020-07-31 2023-02-14 Servier Lab Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
AR125205A1 (es) 2021-03-24 2023-06-21 Servier Lab Nuevo proceso para la síntesis de derivados del ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-dihidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico y su aplicación para la producción de compuestos farmacéuticos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US7432398B2 (en) * 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN103664753B (zh) * 2012-09-04 2017-04-26 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI736531B (zh) * 2015-04-15 2021-08-21 英屬開曼群島商百濟神州有限公司 B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途

Also Published As

Publication number Publication date
MA54063B1 (fr) 2023-06-28
US20210355108A1 (en) 2021-11-18
TWI791916B (zh) 2023-02-11
ES2943511T3 (es) 2023-06-13
IL282565A (en) 2021-06-30
CY1126057T1 (el) 2023-11-15
PH12021550790A1 (en) 2021-10-25
CA3117559C (en) 2023-09-26
MX2021004934A (es) 2021-06-08
EP3873894B1 (en) 2023-03-22
FI3873894T3 (fi) 2023-06-07
MA54063A (fr) 2021-09-08
DOP2021000074A (es) 2021-07-22
AR116921A1 (es) 2021-06-30
RS64236B1 (sr) 2023-06-30
HRP20230563T1 (hr) 2023-08-18
CN112969693A (zh) 2021-06-15
HUE062000T2 (hu) 2023-09-28
CR20210211A (es) 2021-05-25
AU2019370926A1 (en) 2021-05-20
SG11202103594XA (en) 2021-05-28
PT3873894T (pt) 2023-04-28
JOP20210072A1 (ar) 2023-01-30
ZA202102783B (en) 2022-10-26
CA3117559A1 (en) 2020-05-07
PL3873894T3 (pl) 2023-07-31
EP3873894A1 (en) 2021-09-08
SI3873894T1 (sl) 2023-08-31
CL2021000947A1 (es) 2021-11-19
DK3873894T3 (da) 2023-06-06
NI202100025A (es) 2021-08-24
BR112021007194A2 (pt) 2021-07-20
WO2020089281A1 (en) 2020-05-07
CO2021005077A2 (es) 2021-09-20
EA202191143A1 (ru) 2021-09-10
TW202033517A (zh) 2020-09-16
JP2022506137A (ja) 2022-01-17
PE20211503A1 (es) 2021-08-11
GEP20237494B (en) 2023-04-10
KR20210092750A (ko) 2021-07-26

Similar Documents

Publication Publication Date Title
ZA202102783B (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
PH12017501641A1 (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
PT3594199T (pt) 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3502105A4 (en) POLYMORPHIC FORM OF A KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF
IL288348A (en) A method for the synthesis of a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of its salt
IL283656A (en) New crystalline forms of mcl-1 inhibitor, process for their preparation and pharmaceutical preparations containing them
IL289453A (en) A process for the preparation of ridinilazole and crystalline forms thereof
IL282218A (en) New aminopyrimidonyl compounds, a process for their preparation and pharmaceutical preparations containing them
EP4083000A4 (en) PROCESS FOR PREPARING 1,4-CYCLOHEXANEDIMETHANOL
EP3837239A4 (en) PROCESS FOR THE PREPARATION OF SOLRIAMFETOL AND SALT THEREOF
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
EP3398946A4 (en) SALT OF MORPHOLINE DERIVATIVE AND ITS CRYSTALLINE FORM, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL279873A (en) History of amino-pyrimidonyl, process for their preparation and pharmaceutical preparations containing them
EP3877379A4 (en) CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT
IL285453A (en) Preparations for making sweets
EP3814340A4 (en) NOVEL CATECHOLD DERIVATIVES OR THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
IL290215A (en) A process for the preparation of crystalline form ii of sotagliflozin
IL290214A (en) A continuous process for the preparation of crystalline form ii of sotagliflozin
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
EP3840754A4 (en) ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF, AND METHODS OF USE THEREOF
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them